Low persistence rates in rheumatoid arthritis patients treated with triple therapy are attributed to adverse drug events associated with sulfasalazine
Erhardt DP et al. Arthritis Care Res (Hoboken) 2018. doi: 10.1002/acr.23759
Please follow the link below to view this article in full on a third-party website. Note that a subscription or payment may be required.